Role of RANK, RANKL, OPG, and CXCR4 tissue markers in predicting bone metastases in breast cancer patients

Toni Ibrahim, Emanuele Sacanna, Michele Gaudio, Laura Mercatali, Emanuela Scarpi, Wainer Zoli, Patrizia Serra, Rossana Ricci, Luigi Serra, Yibin Kang, Dino Amadori

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Background: The RANK/RANKL/OPG system is active in primary cancers such as breast, prostate, and also in their bone metastases. CXCR4 chemokine receptor is highly expressed in human breast cancer cells and is believed to facilitate the homing of tumor cells to organs such as bone that express high levels of its ligand SDF1. Our study aimed to investigate whether the analysis of these markers with an inexpensive and simple test can help to predict bone metastases in breast cancer patients. Patients and Methods: Marker expression was evaluated by immunohistochemical staining in paraffin-embedded tissue sections of primary breast cancers from 40 individuals: 20 patients with bone metastases (BM), 10 with visceral metastases (VM; considered together as the relapsed group), and 10 with no evidence of disease (NED). Results: RANKL was not detected in tumor cells. OPG- and RANK-positive tumors are found with similar frequency in NED (20%) and in relapsed patients (23% and 17%, respectively). However, in the latter subgroup, only RANK positivity was always associated with bone relapse. The frequency of CXCR4-positive tumors was three-fold higher in relapsed (30%) than in NED (10%) patients and positivity was always linked to bone metastases. Considering NED and VM patients together versus BM patients, we observed that CXCR4 expression, alone (P =.008) or in combination with RANK (P

Original languageEnglish
Pages (from-to)369-375
Number of pages7
JournalClinical Breast Cancer
Volume11
Issue number6
DOIs
Publication statusPublished - 2011

Fingerprint

Breast Neoplasms
Neoplasm Metastasis
Bone and Bones
Neoplasms
CXCR4 Receptors
Chemokine Receptors
Paraffin
Prostate
Breast
Staining and Labeling
Ligands
Recurrence

Keywords

  • Bone metastases
  • Breast cancer
  • CXCR4
  • OPG
  • RANK/RANKL

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Role of RANK, RANKL, OPG, and CXCR4 tissue markers in predicting bone metastases in breast cancer patients. / Ibrahim, Toni; Sacanna, Emanuele; Gaudio, Michele; Mercatali, Laura; Scarpi, Emanuela; Zoli, Wainer; Serra, Patrizia; Ricci, Rossana; Serra, Luigi; Kang, Yibin; Amadori, Dino.

In: Clinical Breast Cancer, Vol. 11, No. 6, 2011, p. 369-375.

Research output: Contribution to journalArticle

Ibrahim, Toni ; Sacanna, Emanuele ; Gaudio, Michele ; Mercatali, Laura ; Scarpi, Emanuela ; Zoli, Wainer ; Serra, Patrizia ; Ricci, Rossana ; Serra, Luigi ; Kang, Yibin ; Amadori, Dino. / Role of RANK, RANKL, OPG, and CXCR4 tissue markers in predicting bone metastases in breast cancer patients. In: Clinical Breast Cancer. 2011 ; Vol. 11, No. 6. pp. 369-375.
@article{cd8344b7dbc94c2ea962f33f772e970e,
title = "Role of RANK, RANKL, OPG, and CXCR4 tissue markers in predicting bone metastases in breast cancer patients",
abstract = "Background: The RANK/RANKL/OPG system is active in primary cancers such as breast, prostate, and also in their bone metastases. CXCR4 chemokine receptor is highly expressed in human breast cancer cells and is believed to facilitate the homing of tumor cells to organs such as bone that express high levels of its ligand SDF1. Our study aimed to investigate whether the analysis of these markers with an inexpensive and simple test can help to predict bone metastases in breast cancer patients. Patients and Methods: Marker expression was evaluated by immunohistochemical staining in paraffin-embedded tissue sections of primary breast cancers from 40 individuals: 20 patients with bone metastases (BM), 10 with visceral metastases (VM; considered together as the relapsed group), and 10 with no evidence of disease (NED). Results: RANKL was not detected in tumor cells. OPG- and RANK-positive tumors are found with similar frequency in NED (20{\%}) and in relapsed patients (23{\%} and 17{\%}, respectively). However, in the latter subgroup, only RANK positivity was always associated with bone relapse. The frequency of CXCR4-positive tumors was three-fold higher in relapsed (30{\%}) than in NED (10{\%}) patients and positivity was always linked to bone metastases. Considering NED and VM patients together versus BM patients, we observed that CXCR4 expression, alone (P =.008) or in combination with RANK (P",
keywords = "Bone metastases, Breast cancer, CXCR4, OPG, RANK/RANKL",
author = "Toni Ibrahim and Emanuele Sacanna and Michele Gaudio and Laura Mercatali and Emanuela Scarpi and Wainer Zoli and Patrizia Serra and Rossana Ricci and Luigi Serra and Yibin Kang and Dino Amadori",
year = "2011",
doi = "10.1016/j.clbc.2011.05.001",
language = "English",
volume = "11",
pages = "369--375",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - Role of RANK, RANKL, OPG, and CXCR4 tissue markers in predicting bone metastases in breast cancer patients

AU - Ibrahim, Toni

AU - Sacanna, Emanuele

AU - Gaudio, Michele

AU - Mercatali, Laura

AU - Scarpi, Emanuela

AU - Zoli, Wainer

AU - Serra, Patrizia

AU - Ricci, Rossana

AU - Serra, Luigi

AU - Kang, Yibin

AU - Amadori, Dino

PY - 2011

Y1 - 2011

N2 - Background: The RANK/RANKL/OPG system is active in primary cancers such as breast, prostate, and also in their bone metastases. CXCR4 chemokine receptor is highly expressed in human breast cancer cells and is believed to facilitate the homing of tumor cells to organs such as bone that express high levels of its ligand SDF1. Our study aimed to investigate whether the analysis of these markers with an inexpensive and simple test can help to predict bone metastases in breast cancer patients. Patients and Methods: Marker expression was evaluated by immunohistochemical staining in paraffin-embedded tissue sections of primary breast cancers from 40 individuals: 20 patients with bone metastases (BM), 10 with visceral metastases (VM; considered together as the relapsed group), and 10 with no evidence of disease (NED). Results: RANKL was not detected in tumor cells. OPG- and RANK-positive tumors are found with similar frequency in NED (20%) and in relapsed patients (23% and 17%, respectively). However, in the latter subgroup, only RANK positivity was always associated with bone relapse. The frequency of CXCR4-positive tumors was three-fold higher in relapsed (30%) than in NED (10%) patients and positivity was always linked to bone metastases. Considering NED and VM patients together versus BM patients, we observed that CXCR4 expression, alone (P =.008) or in combination with RANK (P

AB - Background: The RANK/RANKL/OPG system is active in primary cancers such as breast, prostate, and also in their bone metastases. CXCR4 chemokine receptor is highly expressed in human breast cancer cells and is believed to facilitate the homing of tumor cells to organs such as bone that express high levels of its ligand SDF1. Our study aimed to investigate whether the analysis of these markers with an inexpensive and simple test can help to predict bone metastases in breast cancer patients. Patients and Methods: Marker expression was evaluated by immunohistochemical staining in paraffin-embedded tissue sections of primary breast cancers from 40 individuals: 20 patients with bone metastases (BM), 10 with visceral metastases (VM; considered together as the relapsed group), and 10 with no evidence of disease (NED). Results: RANKL was not detected in tumor cells. OPG- and RANK-positive tumors are found with similar frequency in NED (20%) and in relapsed patients (23% and 17%, respectively). However, in the latter subgroup, only RANK positivity was always associated with bone relapse. The frequency of CXCR4-positive tumors was three-fold higher in relapsed (30%) than in NED (10%) patients and positivity was always linked to bone metastases. Considering NED and VM patients together versus BM patients, we observed that CXCR4 expression, alone (P =.008) or in combination with RANK (P

KW - Bone metastases

KW - Breast cancer

KW - CXCR4

KW - OPG

KW - RANK/RANKL

UR - http://www.scopus.com/inward/record.url?scp=82255191389&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82255191389&partnerID=8YFLogxK

U2 - 10.1016/j.clbc.2011.05.001

DO - 10.1016/j.clbc.2011.05.001

M3 - Article

C2 - 21764390

AN - SCOPUS:82255191389

VL - 11

SP - 369

EP - 375

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

IS - 6

ER -